ONCAlert | AstraZeneca: Pioneers in Ovarian Cancer

Latest NewsMORE >>

According to an update from the phase II KEYNOTE-052 trial presented at the 2017 Global Congress on Bladder Cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses as a first-line treatment for patients with cisplatin-ineligible advanced urothelial cancer.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.